14.10.2015 • News

Bayer to Compensate Swiss Winegrowers

Bayer may have to pay as much as 90 million Swiss francs to compensate winegrowers whose crops treated with its Moon Privilege fungicide suffered damage. The German agrochemical and pharmaceutical giant said it would offer compensation to the Swiss growers without accepting blame. While Bayer said there was “no clear proof,” around 900 Swiss growers have claimed that Moon Privilege was responsible for the poor yields. The affected plants are said to have deformed leaves and dried, shriveled grapes.

According to the Swiss Winegrowers’ Federation, problems related to the fungicide led to a 5% decline in the country’s 2015 grape harvest. A documentary aired in September by Swiss public television station RTS claimed that around 2,000 hectares of the overall 15,000 crops had been affected negatively by Moon Privilege.

Without disclosing the total sum, Bayer said individual offers of compensation would be made to winegrowers beginning in early 2016. The expected payout total was calculated by Winegrowers Federation based on the number of complaints.

The German group said in a statement that while its investigations into the possible cause of the damage were continuing, it believed a combination of factors was in play during the 2014 season, in particular that the growth anomalies mostly arose when Moon Privilege was applied in the final growth phases of the vines and in extremely wet weather.

In September, Bayer advised wine grape growers not to use the fungicide until it had properly investigated the problem. The Swiss Federal Office for Agriculture suspended authorization for Moon Privilege as early as July as a precautionary measure and to avoid further damage in 2016.                                      

Virtual Event

Outsourced Biomanufacturing
Strategic Outsourcing in Biopharmaceuticals

Outsourced Biomanufacturing

April 22, 2026 | Join biopharma professionals, CDMO leaders, and supply chain innovators for a virtual event exploring the future of outsourced biomanufacturing.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.